SCHEMBL4385090

SCHEMBL4385090

O=S(=O)(O)CN1c2ccccc2Sc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 1/20 0.53
PTGS1 P23219 2/20 0.50
PTGS2 P35354 2/20 0.50
BCHE P06276 4/20 0.48
KDM1A O60341 3/20 0.47
PIM1 P11309 1/20 0.46
ACHE P22303 2/20 0.46
NOX1 Q9Y5S8 1/20 0.46
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10023985 0.82 MEN1 (0.58) MEN1KMT2ALMNAPTGS1PTGS2
SCHEMBL48681 0.80 MEN1 (0.58) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL30115198 0.80 MEN1 (0.58) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL30115197 0.80 MEN1 (0.58) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL49291 0.78 PIM1 (0.59) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL8444747 0.78 MEN1 (0.57) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL48847 0.78 MEN1 (0.57) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL31384188 0.78 PIM1 (0.59) MEN1KMT2ALMNAKDM1APIM1
SCHEMBL3774114 0.77 PIM1 (0.58) MEN1KMT2ALMNAKDM1APIM1
Promazine SCHEMBL27679140 0.73 CYP2D6 (0.78) MEN1KMT2ALMNAKDM1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855287-B2 Preparation of high purity phenothiazine N-alkylsulfonates and their use in chemiluminescent assays for the measurement of peroxidase activity CYANAGEN SRL (IT) 2010-12-21 US disclosed
US-7525716-B2 Display device and display apparatus RICOH COMPANY, LTD. (JP) 2009-04-28 US disclosed
US-7489432-B2 Electrochromic display device and display apparatus RICOH COMPANY, LTD. (JP) 2009-02-10 US disclosed
US-20080176251-A1 Preparation of high purity phenothiazine N-alkylsulfonates and their use in chemiluminescent assays for the measurement of peroxidase acitivity CYANAGEN SRL (IT) 2008-07-24 US disclosed
US-20060215250-A1 Electrochromic display device and display apparatus RICOH COMPANY, LTD. (JP) 2006-09-28 US disclosed
US-20060204866-A1 Display device and display apparatus RICOH COMPANY, LTD. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176251-A1 Preparation of high purity phenothiazine N-alkylsulfonates and their use in chemiluminescent assays for the measurement of peroxidase acitivity LPO, ARSA, SULT1E1 MEN1 3072/4885KMT2A 3382/4885LMNA 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.